Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani

Vaccine

Volumn 24, Issue 22, 2006, Pages 4863-4873

  Gamboa Leon R ^a,b   Paraguai de Souza, E ^a   Borja Cabrera, G P ^a   Santos, F N ^a   Myashiro, L M ^a   Pinheiro, R O ^a   Dumonteil, E ^b   Palatnik de Sousa, C B ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSIDAD AUTÓNOMA DE YUCATÁN   (Mexico)

Author keywords

Allium sativum; Immunotherapy; Murine leishmaniasis; Nucleoside hydrolase; Visceral leishmaniasis

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; GARLIC EXTRACT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 4; NUCLEOSIDASE; GLYCOSIDASE; PLANT EXTRACT; PROTOZOAL VACCINE; PROTOZOON ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LYSATE; CELL PROTECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; FEMALE; HUMORAL IMMUNITY; HYPERSENSITIVITY; IMMUNOTHERAPY; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PARASITE EXAMINATION; PHENOTYPE; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN SECRETION; SPLEEN CELL; SURVIVAL RATE; VISCERAL LEISHMANIASIS; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; DELAYED HYPERSENSITIVITY; GARLIC; IMMUNOLOGY;

ANIMALS; ANTIBODIES, PROTOZOAN; FEMALE; GARLIC; HYPERSENSITIVITY, DELAYED; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-4; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; N-GLYCOSYL HYDROLASES; PLANT EXTRACTS; PROTOZOAN VACCINES; VACCINES, DNA;

EID: 33746786089     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.03.005     Document Type: Article

References (53)

1. Schmunis G.A., and López Antuñano F.J. World-wide importance of parasites. In: Colier L., Balows A., and Sussman M. (Eds). Microbial infections (1997), Topley & Wilson 19-38
2. Convit J., Castellano P.L., Rondon A., Penardi M.E., Ulrich M., Castes M., et al. Immunotherapy versus chemoterapy in localized cutaneous leishmaniasis. Lancet 1 (1987) 401-404
3. Mayrink W., Magalhães P.A., Michalick M.S.M., Costa C.A., Lima A.O., Melo M.N., et al. Immunotherapy as treatment of American cutaneous leishmaniasis: preliminary studies in Brazil. Parasitologia 34 (1992) 159-165
4. Toledo V.P., Mayrink W., Gollob K.J., Oliveira M.A., Costa C.A., Genaro O., et al. Immunochemotherapy of American cutaneous leishmaniasis: immunological aspects before and after treatment. Mem Inst Oswaldo Cruz 96 (2002) 89-98
5. Convit J., Ulrich M., Zerpa O., Borges R., Aranzazu N., Valera M., et al. Immunotherapy of Amercian cutaneous leishmaniasis in Venezuela during the period 1990-1999. Trans R Soc Trop Med Hyg 97 (2003) 469-472
6. Tesh R. Control of zoonotic visceral leishmaniasis. Is it time to change strategies?. Am J Trop Med Hyg 52 (1995) 287-292
7. Borja-Cabrera G.P., Cruz Mendes A., Paraguai de Souza W., Okada L.Y.H., Trivellato F.A.A., Kawasaki J.K.A., et al. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 22 (2004) 2234-2243
8. Lanotte G., Rioux JÁ, Pereires J., and Vollhardt Y. Ecologie des leishmanioses dans le sud de la France. 10. Les formes évolutives de la leishmaniose viscérale canine. Elaboration d'une typologie bio-clinique à finalité épidémiologique. Ann Parasitol 54 (1979) 277-295
9. von Reiter I., Kretzschmar A., Boch J., and Krampitz H. Zur leishmaniose des hundes. Infektionsverlauf, diagnose un therapieversuche nach exp. Infection vom Beagles mit Leishmania donovani (st. Kalkutta). Berl Munch Tierarztl Wochenschr 98 (1985) 40-44
10. Lamothe J. Activity of amphotericine B in lipid emulsionin the initial treatment of canine leishmaniasis. J Small Anim Pract 42 (2001) 170-175
11. Alvar J., Molina R., San Andrés M., Tesouro M., Nieto J., Vitutia M., et al. Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy. Ann Trop Med Parasitol 88 (1994) 371-378
12. Gradoni L., Maroli M., Gramiccia M., and Mancianti F. Leishmania infantum infection rates in Phlebotomus perniciosus fed on naturally infected dogs under antimonial treatment. Med Vet Entomol 1 (1987) 339-342
13. Penissi M.G., De Majo M., Masucci M., Britti D., Vitale F., and Del Masso R. Efficacy of the treatment of dogs with leishmaniosis with a combination of metronidazole and spiramycin. Vet Rec 156 (2005) 346-349
14. Oliva G., Foglia Manzillo V., and Pagano A. Canine leishmaniasis: evolution of the chemotherapeutic protocols. Parasitologia 46 (2004) 231-234
15. da Silva V.O., Borja-Cabrera G.P., Correia Pontes N.N., Paraguai de Souza E., Luz K.G., Palatnik M., et al. A phase III trial of Efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amarante, RN). Vaccine 19 (2001) 1082-1092
16. Borja-Cabrera G.P., Correia Pontes N.N., da Silva V.O., Paraguai de Souza E., Santos W.R., Gomes E.M., et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante). Vaccine 20 (2002) 3277-3284
17. ® vaccine blocks the transmission of canine visceral leishmaniasis. Absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs. Vaccine 23 (2005) 4805-4810
18. Santos W.R., de Lima V.M.F., Paraguai de Souza E., Bernardo R.R., Palatnik M., and Palatnik de Sousa C.B. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 21 (2002) 30-43
19. Palatnik de Sousa C.B., Moreno M.B., Paraguai de Souza E., and Borojevic R. The FML vaccine (fucose-mannose ligand) protects hamsters from experimental kala-azar. Ciência e Cultura (J Braz Assoc Adv Sci) 46 (1994) 290-296
20. ® in dogs of Brazilian endemic areas. Third World Congress on Leishmaniosis (Worldleish III), Palermo, Italy; 2005. p. 116.
21. Basu R., Bhaumik S., Basu J.M., Naskar K., De T., and Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and - resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed TH1- and TH2-like responses in visceral leishmaniasis. J Immunol 174 (2005) 7160-7171
22. Sukumaran B., Tewary P., Saxena S., and Madhubala R. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Vaccine 21 (2003) 1292-1299
23. Melby P.C., Yang Y., Zhao W., Perez L.E., and Cheng J. Leishmania donovani p36 (LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun 69 (2001) 4719-4725
24. Gosh A., Labrecque S., and Matlashewski G. Protection against Leishmania donovani infection by DNA vaccination: increased vaccination efficiency through inhibiting the cellular p53 response. Vaccine 19 (2001) 3169-3178
25. Tewary P., Jain M., Sahani M.H., Saxena S., and Madhubala R. A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunotiy against experimental visceral leishmaniasis. J Infect Dis 191 (2005) 2130-2137
26. Rafati S., Nakhaee A., Taheri T., Taslimi Y., Darabi H., Eravani D., et al. Protective vaccination against experimental canine visceral leishmnaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 23 (2005) 3716-3725
27. Ramiro M.J., Zárate J.J., Hanke T., Rodriguez D., Rodriguez J.R., Esteban M., et al. Protection in dogs agaisnt visceral leishmaniasis caused by Leishmania infantum is acheived by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 21 (2003) 2474-2484
28. Handman E., Noormohanmmadai A.H., Curtis J.M., Baldwin T., and Sjolander A. Therapy of murine cutaneous leishmaniasis by DNA vaccination. Vaccine 18 (2000) 3011-3017
29. Santos W.R., Aguiar I.A., Paraguai de Souza E., de Lima V.F.M., Palatnik M., and Palatnik-de-Sousa C.B. Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine. Vaccine 21 32 (2003) 4668-4676
30. Santos FN, Borja Cabrera GP, Paraguai de Souza E, Reis AB, Assis Filho O, Palatnik-de-Sousa CB. Immunotherapy against experimental canine visceral leishmaniasis with the industrialized FML-vaccine leishmune (1 mg saponin adjuvant). Abstracts of the Third World Congress on Leishmaniosis (Worldleish III), Palermo, Italy; 2005. p. 204.
31. Santana D.M., Paraguai de Souza E., Borja-Cabrera G.P., Sturm N.R., Palatnik de Sousa C.B., and Campbell D.A. Nucleoside hydrolase from Leishmania (L.) donovani is an antigen diagnostic for visceral leishmaniasis. Mol Biochem Parasitol 120 (2002) 315-319
32. Aguilar-Be I., Zardo R.S., Paraguai de Souza E., Borja-Cabrera G.P., Rosado-Vallado M., Mut-Martin M., et al. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect Immun 73 (2005) 812-819
33. Ghazanfari T., Hassan Z.M., Ebtekar M., Ahmadiani A., Naderi G., and Azar A. Garlic induces a shift in cytokine pattern in Leishmania major-infected Balb/c mice. Sand J Immunol 52 (2000) 491-495
34. Ghazanfari T., Hassan Z.M., and Khamesipour A. Enhancement of peritoneal macrophage phagocytic activity agaisnt Leishmania major by garlic (Allium sativum) treatment. J Ethnopharamacol 103 (2006) 333-337
35. Bradley D.J., and Kirkley K. Regulation of Leishmania population within the host. The variable course of Leishmania donovani infections in the mice. Clin Exp Immunol 30 (1977) 119-129
36. Ulczak O.M., Ghadirian E., Skamene E., Blackwell J.M., and Kongshavn. Characterization of protective T cells in the acquired response to Leishmania donovani in genetically determined cure (H-2b) and noncure (H-2d) mouse strains. Infect Immun 57 (1989) 2892-2899
37. Maina C.V., Riggs P.D., Grandea III A.G., Slatko B.E., Moran L.S., Tagliamonte J.A., et al. A vector to express and purify foreign proteins in Escherichia coli by fusion to, and separation from, maltose binding protein. Gene 74 (1988) 365-373
38. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the folin phenol reagent. J Biol Chem 193 (1951) 265-275
39. Mendes C.O., Paraguai de Souza E., Borja-Cabrera G.P., Melo Batista L.M., Santos M.A., Parra L.E., et al. IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniasis. Vaccine 21 (2003) 2589-2597
40. Iborra S., Soto M., Carrion J., Alonso C., and Requena J.M. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniasis. Vaccine 22 (2004) 3865-3876
41. Guarga J.L., Moreno J., Lucientes J., Gracia M.J., Peribanez M.A., Alvar J., et al. Canine leishmaniasis transmission: higher infectivity among naturally infected dogs to sandflies is associated with lower proportions of T helper cells. Res Vet Sci 69 (2000) 249-253
42. Hailu A., van Baarle D., Knol G.J., Berhe N., Miedema F., and Kager P.A. T cell subset and cytokine profiles in human visceral leishmaniasis during active and asymptomatic or sub-clinical infection with Leishmania donovani. Clin Immunol 117 (2005) 182-191
43. Ghazanfari T., Hassan Z.M., and Ebrahimi M. Immunomodulatory activity of a protein isolated from garlic extract on delayed type of hypersensitivity. Int Immunopharmacol 2 (2002) 1541-1549
44. Lau B.H.S., Yamasaki T., and Gridley D.S. Garlic compounds modulate macrophage and T-lymphocyte functions. Mol Biother 3 (1991) 103-107
45. Morioka N., Sze L.L., Moron D.L., and Irie R.F. A protein fraction from aged garlic extract enhances cytotoxicity and proliferation of human lymphocytes mediated by IL-2 and concanavalin A. Cancer Immunol Immunother 37 (1993) 316-322
46. Jeong H.G., and Lee Y.W. Protective effects of dyallil sulfide on N-nitrosodimethylamine-induced immunosupression in mice. Cancer Immunol Immunother 134 (1998) 73-79
47. Tang Z., Sheng Z., and Liu S. The preventing function of garlic on experimental oral precancer and its effect on natural killer cells, T lymphocytes and interleukin-2. Hunani Ko Ta-Hsueh Hsueh Pao 22 (1997) 246-248
48. Taylor A.P., and Murray H.W. Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin IL-12 in experimental visceral leishmaniasis in interferon-gamma gene-disrupted mice. J Exp Med 185 (1997) 1231-1239
49. Goto H., and Lindoso J.A.L. Immunity and immunosupression in experimental visceral leishmanaisis. Braz J Med Biol Res 37 (2004) 615-623
50. WHO. Guidelines for the evaluation of Plasmodium falciparum vaccines in populations exposed to natural infection. TDR/MAL/VAC; 1997, p. 1-54.
51. Mayrink W., Genaro O., França Silva J.C., da Costa R.T., Tafuri W.L., Peixoto Toledo V.C., et al. Phase I and II open clinical trials of a vaccine against Leishmania (L.) chagasi infections in dogs. Mem Inst Osw Cruz (MEMIOC) 91 (1996) 695-697
52. Genaro O., Pinto J.A., da Costa C.A., França Silva J.C., Costa R.T., Silva J.C., et al. Phase III randomized double blind clinical trial of the efficacy of a vaccine against canine visceral leishmaniasis in urban area of Montes Claros, MG, Brazil. Mem Inst Osw Cruz (MEMIOC) 91 Suppl. I (1996) 166
53. Handman E. Leishmaniasis: current stauts of vaccine development. Clin Microbiol Rev 14 (2001) 229-243